Abstract
Alpha-1 antitrypsin (AAT) is the most abundant proteinase inhibitor within the circulation and AAT deficiency is a genetic disorder characterised by serum levels of less than 11μmol/L. The Z mutation is the most common AAT allele associated with the disease and causes the most severe plasma deficiency, as the mutant protein polymerizes and accumulates within the endoplasmic reticulum of hepatocytes. The retained polymers are associated with cirrhosis and reduced serum levels of AAT contribute to the development of chronic pulmonary disease in AAT deficient individuals. This article will review the importance of AAT as a serine anti-protease, the clinical manifestations of AAT deficiency and specific treatment of the disease. Current therapies including AAT replacement and treatment with synthetic or alternative protease inhibitors are reviewed, along with possible future therapies including those focusing on targeting AAT polymer formation or based on gene therapy.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Volume: 9 Issue: 4
Author(s): Emer P. Reeves, Sonya Cosgrove, David A. Bergin, Catherine M. Greene and Noel G. McElvaney
Affiliation:
Abstract: Alpha-1 antitrypsin (AAT) is the most abundant proteinase inhibitor within the circulation and AAT deficiency is a genetic disorder characterised by serum levels of less than 11μmol/L. The Z mutation is the most common AAT allele associated with the disease and causes the most severe plasma deficiency, as the mutant protein polymerizes and accumulates within the endoplasmic reticulum of hepatocytes. The retained polymers are associated with cirrhosis and reduced serum levels of AAT contribute to the development of chronic pulmonary disease in AAT deficient individuals. This article will review the importance of AAT as a serine anti-protease, the clinical manifestations of AAT deficiency and specific treatment of the disease. Current therapies including AAT replacement and treatment with synthetic or alternative protease inhibitors are reviewed, along with possible future therapies including those focusing on targeting AAT polymer formation or based on gene therapy.
Export Options
About this article
Cite this article as:
P. Reeves Emer, Cosgrove Sonya, A. Bergin David, M. Greene Catherine and G. McElvaney Noel, New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (4) . https://dx.doi.org/10.2174/1871523011009040314
DOI https://dx.doi.org/10.2174/1871523011009040314 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry
Current Drug Metabolism Insulin-Degrading Enzyme: Structure-Function Relationship and its Possible Roles in Health and Disease
Current Pharmaceutical Design Multiple Roles of the Extracellular Matrix in Inflammation
Current Pharmaceutical Design Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Hendra and Nipah Viruses: Pathogenesis and Therapeutics
Current Molecular Medicine Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews Hypertension and Diabetes: Emphasis on the Renin-Angiotensin System in Atherosclerosis
Current Hypertension Reviews PPARs as Drug Targets to Modulate Inflammatory Responses?
Current Drug Targets - Inflammation & Allergy Effectiveness and Efficiency of Platelet Rich Plasma in the Treatment of Diabetic Ulcers
Current Pharmaceutical Biotechnology Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device through Turbiscan Lab Expert
Medicinal Chemistry Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases
Current Medicinal Chemistry Leptin and Vascular Smooth Muscle Cells
Current Pharmaceutical Design Modulation of the Immune Response by Targeting Endothelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews (Discontinued)